NCT06913023 - Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 5, 2026

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions

Kidney Transplant Recipient

Interventions

DRUG

Semaglutide 3 MG [Rybelsus]

Semaglutide 3mg for 4 weeks.

DRUG

Semaglutide 7 MG [Rybelsus]

Semaglutide 7mg for 4 weeks.

DRUG

Semaglutide 14 MG [Rybelsus]

Semaglutide 14mg for 16 weeks.

DRUG

Placebo Oral Tablet

Placebo tablet

Trial Locations (2)

St. Paul's Hospital, Vancouver

Toronto General Hospital, Toronto

All Listed Sponsors

lead

University Health Network, Toronto

OTHER